Literature DB >> 17510437

Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors.

Sophia S Wang1, Wendy Cozen, James R Cerhan, Joanne S Colt, Lindsay M Morton, Eric A Engels, Scott Davis, Richard K Severson, Nathaniel Rothman, Stephen J Chanock, Patricia Hartge.   

Abstract

Two common single nucleotide polymorphisms in immunoregulatory genes (TNF G308A, rs1800629 and IL10 T3575A, rs1800890) have been recently reported as risk factors for non-Hodgkin lymphoma (NHL) in a large pooled analysis. We systematically investigated the effects of other established NHL risk factors in relation to the tumor necrosis factor (TNF) G308A or interleukin 10 (IL10) T3575A genotypes. We calculated odds ratios (OR) and 95% confidence intervals (95% CI) from 1,172 cases and 982 population-based controls in a U.S. multicenter study. We investigated NHL overall and two common subtypes [diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma]. NHL risks were increased among those with both an autoimmune condition and the TNF G308A GA/AA (OR(NHL), 2.1; 95% CI, 1.0-4.2) or the IL10 T3575A TA/AA genotype (OR(NHL), 1.6; 95% CI, 0.9-2.6) compared with individuals without an autoimmune condition and with the common TNF G308A GG or IL10 T3575A TT genotype, respectively; results were similar for DLBCL and follicular lymphoma. We found that elevated DLBCL risk associated with last-born status was more pronounced among those with TNF G308A GA/AA (OR(DLBCL), 2.7; 95% CI, 1.1-6.4) or IL10 T3575A TA/AA (OR(DLBCL), 2.9; 95% CI, 1.6-5.2). Similarly, elevated DLBCL risk associated with obesity (body mass index, > or = 35 versus <25 kg/m(2)) was observed only among those with TNF G308A GA/AA (OR(DLBCL), 2.5; 95% CI, 1.1-5.7) or IL10 T3575A TA/AA genotypes (OR(DLBCL), 2.0; 95% CI, 1.1-3.5). These exploratory results require replication but provide evidence that autoimmune conditions, late birth order, and obesity act partly through a common inflammatory pathway, posing a greater risk to individuals with variant TNF and IL10 genotypes than those with wild-type alleles.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17510437     DOI: 10.1158/0008-5472.CAN-06-4752

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

Review 1.  Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma.

Authors:  Catarina Dias; David A Isenberg
Journal:  Nat Rev Rheumatol       Date:  2011-06       Impact factor: 20.543

2.  Association of the four common polymorphisms in interleukin-10 (rs1800890, rs1800896, rs1800871, and rs1800872) with non-Hodgkin's lymphoma risk: a meta-analysis.

Authors:  Zhi-Ming Dai; Ai-Li He; Wang-Gang Zhang; Jie Liu; Xing-Mei Cao; Yin-Xia Chen; Xiao-Rong Ma; Wan-Hong Zhao; Zhi-Jun Dai
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 3.  Pathophysiology of retinal lymphoma.

Authors:  Sarah E Coupland; Chi Chao Chan; Justine Smith
Journal:  Ocul Immunol Inflamm       Date:  2009 Jul-Aug       Impact factor: 3.070

Review 4.  Association of Interleukin-10 -3575T>A and -1082A>G polymorphisms with non-Hodgkin lymphoma susceptibility: a comprehensive review and meta-analysis.

Authors:  Yan Zhang; Zu-Guang Xia; Jin-Hong Zhu; Min-Bin Chen; Tong-Min Wang; Wen-Xiang Shen; Jing He
Journal:  Mol Genet Genomics       Date:  2015-05-15       Impact factor: 3.291

5.  Examining racial differences in diffuse large B-cell lymphoma presentation and survival.

Authors:  Christopher R Flowers; Pareen J Shenoy; Uma Borate; Kevin Bumpers; Tanyanika Douglas-Holland; Nassoma King; Otis W Brawley; Joseph Lipscomb; Mary Jo Lechowicz; Rajni Sinha; Rajinder S Grover; Leon Bernal-Mizrachi; Jeanne Kowalski; Will Donnellan; Angelina The; Vishnu Reddy; David L Jaye; James Foran
Journal:  Leuk Lymphoma       Date:  2013-02

6.  Polymorphisms in pattern-recognition genes in the innate immunity system and risk of non-Hodgkin lymphoma.

Authors:  Wei Hu; Bryan A Bassig; Jun Xu; Tongzhang Zheng; Yawei Zhang; Sonja I Berndt; Theodore R Holford; H Dean Hosgood; Brian Leaderer; Meredith Yeager; Idan Menashe; Peter Boyle; Kaiyong Zou; Yong Zhu; Stephen Chanock; Qing Lan; Nathaniel Rothman
Journal:  Environ Mol Mutagen       Date:  2012-10-11       Impact factor: 3.216

Review 7.  To Each Its Own: Linking the Biology and Epidemiology of NHL Subtypes.

Authors:  Jean L Koff; Dai Chihara; Anh Phan; Loretta J Nastoupil; Jessica N Williams; Christopher R Flowers
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

8.  Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium.

Authors:  Eleanor Kane; Christine F Skibola; Paige M Bracci; James R Cerhan; Laura Costas; Karin Ekström Smedby; Elizabeth A Holly; Marc Maynadié; Anne J Novak; Tracy J Lightfoot; Stephen M Ansell; Alex G Smith; Mark Liebow; Mads Melbye; Lindsay Morton; Silvia de Sanjosé; Susan L Slager; Sophia S Wang; Yawei Zhang; Tongzhang Zheng; Eve Roman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-05-11       Impact factor: 4.254

9.  Variants in inflammation genes and the risk of biliary tract cancers and stones: a population-based study in China.

Authors:  Ann W Hsing; Lori C Sakoda; Asif Rashid; Gabriella Andreotti; Jinbo Chen; Bin-Shen Wang; Ming-Chang Shen; Bingshu E Chen; Philip S Rosenberg; Mingdong Zhang; Shelley Niwa; Lisa Chu; Robert Welch; Meredith Yeager; Joseph F Fraumeni; Yu-Tang Gao; Stephen J Chanock
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

10.  Etiologic heterogeneity among non-Hodgkin lymphoma subtypes.

Authors:  Lindsay M Morton; Sophia S Wang; Wendy Cozen; Martha S Linet; Nilanjan Chatterjee; Scott Davis; Richard K Severson; Joanne S Colt; Mohammad A Vasef; Nathaniel Rothman; Aaron Blair; Leslie Bernstein; Amanda J Cross; Anneclaire J De Roos; Eric A Engels; David W Hein; Deirdre A Hill; Linda E Kelemen; Unhee Lim; Charles F Lynch; Maryjean Schenk; Sholom Wacholder; Mary H Ward; Shelia Hoar Zahm; Stephen J Chanock; James R Cerhan; Patricia Hartge
Journal:  Blood       Date:  2008-09-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.